Shares of Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) are scheduled to reverse split on the morning of Monday, October 28th. The 1-10 reverse split was announced on Tuesday, October 15th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, October 25th.
Kazia Therapeutics Stock Performance
Shares of Kazia Therapeutics stock opened at $0.58 on Thursday. The firm’s 50-day simple moving average is $0.40 and its 200-day simple moving average is $0.36. Kazia Therapeutics has a 1 year low of $0.19 and a 1 year high of $1.58.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Kazia Therapeutics in a research report on Friday, July 12th.
About Kazia Therapeutics
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Featured Articles
- Five stocks we like better than Kazia Therapeutics
- What to Know About Investing in Penny Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is a Stock Market Index and How Do You Use Them?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is a buyback in stocks? A comprehensive guide for investors
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
